Drug Profile
Research programme: anti-infective vaccines - GlobeImmune
Alternative Names: GI-18000; GI-19000; GI-2010; GI-5001; Hepatitis C vaccine - GlobeImmune; HIV vaccine - GlobeImmune/HVTN; HIVAX-GSLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator GlobeImmune
- Developer GlobeImmune; HIV Vaccine Trials Network
- Class AIDS vaccines; Hepatitis C vaccines; Tuberculosis vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tuberculosis
- No development reported Hepatitis C; Hepatitis D; HIV infections
Most Recent Events
- 22 Feb 2023 GI 18000 is still in preclinical trials for Tubersulosis in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Hepatitis-D in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Tuberculosis in USA